#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Solitary fibrous tumour Trigeminal neuralgia Anal squamous cell carcinoma Paraneoplastic neurological syndrome Craniocerebral injury Peritoneal mesothelioma malignant Fatty acid oxidation disorder Li-Fraumeni syndrome Crigler-Najjar syndrome Liposarcoma Pyoderma gangrenosum Vulval cancer Haemolytic uraemic syndrome Juvenile chronic myelomonocytic leukaemia Neoplasm malignant More trials…

    Learn about Rare Diseases

    Pleural mesothelioma malignant – Basic Information Waldenstrom’s macroglobulinaemia refractory – Treatment Inclusion body myositis – Life with Disease Fabry’s disease – Treatment Urea cycle disorder Von Willebrand’s disease – Life with Disease Mitochondrial myopathy – Basic Information Stevens-Johnson syndrome – Basic Information Undifferentiated sarcoma – Basic Information Aicardi-Goutieres syndrome – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Erlotinib Tolebrutinib Temsirolimus Siponimod Ziltivekimab Nicotine Tralokinumab S227928 Alendronic Acid Furosemide Ph. Eur. Fenebrutinib SULBACTAM SODIUM Gad20-209-Fsp-A4 Ripretinib IMB 101 Hydrochlorothiazide OLVEREMBATINIB Enasidenib Mesilate [89ZR]ZR-DFO-CIT-013 Vibozilimod More therapies…

    Learn about Your Condition

    Diabetic gastroparesis Vulvovaginal pruritus Inflammatory bowel disease Hypertrophic cardiomyopathy Obstructive airways disorder Basal cell carcinoma Rectal neoplasm Perthes disease Hypertriglyceridaemia Portal hypertension Open angle glaucoma Bronchiectasis Cervix carcinoma Raynaud's phenomenon Hypophosphatasia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Centre Hospitalier De Versailles

Centre Hospitalier De Versailles

177 Rue De Versailles, Le Chesnay, Le Chesnay-Rocquencourt, 78150, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study on the Effectiveness of High-Dose Vitamin C for Patients with Shock After Cardiac Arrest

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Ascorbic Acid
    • Dobutamine
    • Epinephrine
    France

  • Study on Azacitidine and Gilteritinib for Adults with Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Acute myeloid leukaemia
    Investigated Drugs:
    • Azacitidine
    • Gilteritinib
    France

  • Study on Alpelisib and Fulvestrant or Ribociclib and Fulvestrant for Patients with HR+, HER2- Metastatic Breast Cancer with PIK3CA Mutations

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    Investigated Drugs:
    • Alpelisib
    • Fulvestrant
    • Goserelin
    France

  • Study on Milvexian and Drug Combination for Patients Recovering from a Heart Attack

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Acetylsalicylic Acid
    • Clopidogrel
    • Milvexian
    Austria Belgium Bulgaria Croatia Czechia Denmark +14

  • Study of oseltamivir and paracetamol blood levels in critically ill patients with severe influenza requiring mechanical ventilation

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Oseltamivir
    • Paracetamol
    France

  • Study on Dobutamine and Glucose for Patients with Septic Cardiomyopathy and Low Blood Flow

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Sepsis
    Investigated Drugs:
    • Dobutamine Hydrochloride
    • Glucose Monohydrate
    France

  • Study of Pioglitazone and Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia Patients After Stopping Treatment Attempts

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Chronic myeloid leukaemia
    Investigated Drugs:
    • Pioglitazone
    France

  • Study on Isatuximab, Lenalidomide, and Dexamethasone for Elderly Patients with Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Bortezomib
    • Dexamethasone
    • Isatuximab
    France

  • Study on Improving Survival in Acute Myeloid Leukemia for Adults Aged 18-60 Using Idarubicin, Daunorubicin, Cytarabine, and Mycophenolic Acid

    Not recruiting

    4 1 1 1
    Investigated Diseases:
    • Acute myeloid leukaemia
    Investigated Drugs:
    • Cytarabine
    • Venetoclax
    France

  • Study of Hydrocortisone and Vasopressin (Argipressin) Treatment in Adult Patients with Post-Cardiac Arrest Syndrome and Hemodynamic Failure

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Cardiac arrest
    Investigated Drugs:
    • Argipressin
    • Hydrocortisone
    • Sodium Chloride
    France
Previous Page
1 … 10 11 12 13
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!